tbuckley/cabot-search huggingface dataset:
Treatment of the Hypereosinophilic Syndrome with Interferon-α
Authors: Thomas Papo
Journal: Annals of Internal Medicine (1995)

Letters15 July 1995Treatment of the Hypereosinophilic Syndrome with Interferon-αThomas Papo, Jean-Charles Piette, and Olivier HermineThomas Papo, Jean-Charles Piette, and Olivier HermineAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-123-2-199507150-00017 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Butterfield and Gleich [1] reported that interferon-α was efficient in five of six patients with the idiopathic hypereosinophilic syndrome. We report a case of hypereosinophilic syndrome that was refractory to interferon therapy and was successfully treated with oral etoposide.A 59-year-old man had had defined idiopathic hypereosinophilic syndrome since 1991. High-grade fever and bloody diarrhea with abdominal cramps were temporally associated with high eosinophil counts. Moderate splenomegaly and lower limb dysesthesia caused by axonal polyneuropathy were consistently found. The eosinophil count before any specific treatment was 20 000 cells/mm3. IgE and vitamin B12 levels were normal. Examination ...References1. Butterfield JH, Gleich GJ. Interferon-α treatment of six patients with the idiopathic hypereosinophilic syndrome. Ann Intern Med. 1994; 121:648-53. Google Scholar2. Smit AJ, van Essen LH, de Vries EG. Successful long-term control of idiopathic hypereosinophilic syndrome with etoposide. Cancer. 1991; 67:2826-7. Google Scholar Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byA critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophiliaTreatment of Hypereosinophilic Syndromes with Prednisone, Hydroxyurea, and InterferonAtypical Myeloproliferative Disorders: Diagnosis and ManagementTraitement des hyperéosinophiliesInterferon Treatment for Hypereosinophilic Syndromes and Systemic MastocytosisModern Diagnosis and Treatment of Primary EosinophiliaComplete Remission of Hypereosinophilic Syndrome after Interferon-α Therapy: Report of a Case and Literature Review 15 July 1995Volume 123, Issue 2Page: 155-156KeywordsBiopsyEosinophilsFeversInterferonsKaryotypesLymphoproliferative disorderParalysisSmall intestineSplenomegalyUlcers Issue Published: 15 July 1995 Copyright & PermissionsCopyright © 1995 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Use of Cardiac Resynchronization Therapy in Patients Hospitalized With Heart Failure
Authors: Jonathan P. Piccini, Adrian F. Hernandez, David Dai, Kevin L. Thomas, William R. Lewis, Clyde W. Yancy, Eric D. Peterson, Gregg C. Fonarow
Journal: Circulation (2008)

The frequency and characterization of patients receiving cardiac resynchronization therapy (CRT) are largely unknown since the publication of pivotal clinical trials and subsequent incorporation of CRT into the American College of Cardiology/American Heart Association guidelines for heart failure.We analyzed 33,898 patients admitted from January 2005 through September 2007 to 228 hospitals participating in the American Heart Association's Get With the Guidelines-Heart Failure program. There were 4201 patients (12.4%) discharged alive with CRT, including 811 new implants. Patients discharged with CRT were older (median age, 75 versus 72 years) and had lower median left ventricular ejection fraction (30% versus 38%), more frequent ischemic cardiomyopathy (58% versus 45%), more history of atrial fibrillation (38% versus 27%), and higher rates of beta-blocker and aldosterone antagonist use (P<0.0001 for all) than those without CRT. We found that 4.8% of patients with left ventricular ejection fraction <or=35% were discharged with a new CRT implant, which varied greatly by hospital. Ten percent of patients discharged with a new CRT implant had a left ventricular ejection fraction >35%. Major factors associated with lower rates of new CRT placement were treatment in the northeast (odds ratio, 0.40; 95% confidence interval, 0.30 to 0.53), black race (odds ratio, 0.45; 95% confidence interval, 0.36 to 0.57), increasing left ventricular ejection fraction per 10% (odds ratio, 0.56; 95% confidence interval, 0.52 to 0.60), and increasing age per 10 years in those >70 years of age (odds ratio, 0.56; 95% confidence interval, 0.48 to 0.65).Although CRT is a recent evidence-based therapy for heart failure, patterns of use differ significantly from clinical trials and published guidelines. Important variations also exist for CRT therapy based on race, geographic region, comorbidities, and age and need to be addressed through further study and/or quality-of-care initiatives.
Abstract 3024: Methylation analysis of the VDR gene in ovarian normal and tumorous tissue
Authors: Matthew Poulin, Ann Meyer, Andrew Bartley, Qin Guo, Jessica Xu, Liying Yan
Journal: Cancer Research (2011)

Abstract Ovarian cancer remains the most lethal gynaecological cancer. Various molecular changes have been identified and have shown promise for their diagnostic, prognostic and curative capacity but still need further validation. Vitamin D has been shown to play a role in the suppression of tumor growth and in the modification of some properties of fully transformed malignant cells. In light of evidence for promoter methylation of the vitamin D receptor in the control of the expression of this gene, we have designed methylation assays that cover many regions of this gene in order to determine its methylation profile in normal individuals, ovarian tumors and ovarian cell lines. This gene is highly polymorphic and SNP assays were also designed to analyze the genetic variability within the VDR gene as well. In order to determine if the methylation state and/or the genetic make-up within the VDR gene plays a role in ovarian cancer we analyzed 76 CpG sites and 20 SNPs in normal male blood DNA and tumor sample DNA. We determined the base-line methylation and genetic state in a non-cancerous sample and found that the promoter region from -700 from the transcriptional start site, through the 5’UTR and into intron 1 shows very low or no methylation. Conversely the CpG sites at the intron 10/Exon 11 boundaries were very highly methylated in normal blood DNA. We examined these same regions in 10 sets of ovarian tumors and their corresponding normal surrounding tissue. There is a small increase in methylation around -700 region in the tumor tissue compared to the normal blood DNA. Some cell line showed higher levels of methylation as well. COV318 has an elevated level of methylation and so has SKOV, OB58, and OV17r. There was no significant difference, however, between tumor/normal samples starting from -500 into intron 1. The methylation level in these samples is all very low. Within the intron 10/exon 11 region, a majority of the tumors show slightly higher levels of methylation than the normal tissue. The T&amp;gt;C SNP rs731236 at the intron 10/exon 11 boundary is within a CpG site that gives an interesting methylation profile between some of the samples that will be presented. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3024. doi:10.1158/1538-7445.AM2011-3024
Indications for systemic steroids in dermatology
Authors: ALAN LYELL
Journal: British Journal of Dermatology (1976)

Journal Article Indications for systemic steroids in dermatology Get access ALAN LYELL ALAN LYELL Department of Dermatology, Glasgow Royal Infirmary Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 94, Issue s12, 1 March 1976, Pages 131–133, https://doi.org/10.1111/j.1365-2133.1976.tb02283.x Published: 01 March 1976
A SIMPLE AND SAFE OPERATION ON THE FRONTAL SINUS BY THE INTRA-NASAL ROUTE.
Authors: R. H. GOOD
Journal: JAMA (1907)

The instruments used in this operation are two frontal sinus rasps, two tapering curved chisels and three protectors. The frontal sinus rasp (Fig. 1) is made on the same principle as the old-fashioned coarse horseshoe rasp, from which I derived the idea. It is slightly curved at the rasp end to fit into the frontal sinus and the teeth are on the longitudinally concave surface, pointing toward the handle, so that when traction is made on the rasp, the bone anterior to it is rasped away, as illustrated in Figure 5. The posterior surface of the rasp is perfectly smooth and flat. The chisels (Fig. 2) are short, curved and tapering. The handle at the chisel end is very slender so that the chisel can be manipulated under the direct vision of the eye. The edges are tapering as well as blunt, so that if the edge should strike a
Randomised controlled trial of pelvic floor muscle training during pregnancy
Authors: Kjell Å Salvesen, Siv Mørkved
Journal: BMJ (2004)

IFN-γ contains a nuclear localization sequence that may play a role in the nuclear transport of activated STAT1α via a complex of IFN-γ/IFN-γ receptor (IFNGR)-1/STAT1α with the nuclear importer nucleoprotein interactor 1. In this study, we examine the mechanism of endocytosis of IFNGR-1 and the relationship of its nuclear translocation to that of STAT1α. In untreated WISH cells, both IFNGR-1 and IFNGR-2 were constitutively localized within caveolae-like microdomains isolated from plasma membrane. However, treatment of cells with IFN-γ resulted in rapid migration of IFNGR-1, but not IFNGR-2, from these microdomains. Filipin pretreatment, which specifically inhibits endocytosis from caveolae-like microdomains, inhibited the nuclear translocation of IFN-γ and IFNGR-1 as well as the tyrosine phosphorylation and nuclear translocation of STAT1α, but did not affect the binding of IFN-γ to these cells. In the Jurkat T lymphocyte cell line, which does not express caveolin-1, nuclear translocation of IFNGR-1 and STAT1α were similarly inhibited by filipin pretreatment. Isolation of lipid microdomains from Jurkat cells showed that both IFNGR-1 and IFNGR-2 were associated with lipid microdomains only after stimulation with IFN-γ, suggesting that the IFNGR subunits are recruited to lipid microdomains by IFN-γ binding in lymphocytes (Jurkat) in contrast to their constitutive presence in epithelial (WISH) cells. In contrast, treatments that block clathrin-dependent endocytosis did not inhibit either activation or nuclear translocation of STAT1α or the nuclear translocation of IFN-γ or IFNGR-1. Thus, membrane lipid microdomains play an important role in IFN-γ-initiated endocytic events involving IFNGR-1, and the nuclear translocation of IFN-γ, IFNGR-1, and STAT1α.
Tying Fallopian Tubes to Ovarian Cancer Risk
Authors: S. Jenks
Journal: JNCI Journal of the National Cancer Institute (2012)

I ncreasing evidence suggests that the fallopian tubes — once seen as an extremely rare site for cancer — could be the source of the most aggressive ovarian cancer. Last April, investigators at the Dana – Farber Cancer Institute in Boston immortalized fallopian tube cells in the lab, inducing the process by which ovarian cancer progresses from these reproductive tubes to high-grade serous tumors in the ovary: the deadliest, most common form of the disease. “For all those disbelievers out there, this hopefully is the nail in the coffi n,” said Jessica McAlpine, M.D. , an assistant professor in the University of British Columbia ’ s department of gynecology and obstetrics, referring to the April article in the Proceedings of the National Academy of Sciences . “Obviously, there ’ s a need for further study, but we need to do something about it now.” In Canada, researchers have begun urging gynecologists to routinely remove the fallopian tubes in place of a tubal ligation, or during a hysterectomy, even if a woman is not at high risk for ovarian cancer. By convention, current practice leaves these tubes in place. “For a woman who wants to have her tubes tied, she ’ s already decided against having more or any children, so instead of tying the tubes, why not take them out?” McAlpine asked. “And, in a hysterectomy, it ’ s easier to remove the fallopian tubes and keep the ovaries for their hormonal function. We think that reduces the risk not only for ovarian cancer but for other [gynecologic] cancers as well.” Preserving ovarian function, especially in younger women, would also stave off premature menopause with all its attendant health risks, she said, including heart disease, osteoporosis, dementia, and stroke.
Immunofluorescent localization of antithrombin III in human skin
Authors: M.C.J.M. JONG, C.M. WALSTRA
Journal: British Journal of Dermatology (1982)

The presence in clinically normal human skin of the proteinase inhibitor antithrombin III (ATIII) has been studied by indirect immunofluorescence (IF) microscopy. The IF staining reaction for ATIII in skin tissue sections was most prominent in vessel wall structures. The simultaneous use of fluorescent staining techniques for nuclear DNA revealed that ATIII antigen tends to be concentrated at the level of the vascular endothelial basement membrane, in contrast to the typical intra-endothelial distribution of Factor VIII related antigen. Although our findings indicate that ATIII is normally associated with dermal vessel walls, it remains to be seen whether its presence there is of importance, e.g. in modulating inflammatory skin responses.
Abstract 591: Host cell DNA damage and inflammation responses determine oncolytic adenovirus efficacy in ovarian cancer
Authors: Michael A. Salako, Claire M. Connell, Atsushi Shibata, Vilma Graupner, Michelle Lockley, Frances R. Balkwill, Iain A. McNeish
Journal: Cancer Research (2010)

Abstract Introduction. Oncolytic adenoviruses show promise as a cancer treatment, by replicating selectively within malignant cells. Viral replication requires multiple cell cycle checkpoints to be overcome. Ovarian cancer sensitivity to viral cytotoxicity varies greatly, even between cells with similar infectivity and intracellular virion production. Viruses also generate acute inflammatory responses with production of cytokines, especially TNF-α. We investigated the role of cellular DNA damage in efficacy of adenovirus dl922-947 in ovarian cancer and also whether inhibition of TNF-α augments activity. Methods. Host DNA damage and repair pathways were assessed in ovarian cancer lines, TOV21G, IGROV1 and A2780CP, which cover three-log range of virus sensitivity. The ATR-chk1 pathway was inhibited using siRNA and UCN-01 treatment. In addition, inflammatory cytokine responses to dl922-947 were assessed in vitro and in xenograft models. TNF-α was inhibited using shRNA and monoclonal antibodies. Results. Oncolytic adenovirus cytotoxicity is associated with extensive genomic DNA damage. Following infection, sensitive, but not resistant, ovarian cancer cells activate cdc25a and over-replicate genomic DNA, creating extensive double-strand breaks. Inhibition of ATR-chk1 in resistant cells augments cdc25a activity and increases genomic DNA over-replication. This enhances cytotoxicity without increasing E1A expression or viral replication. In addition, dl922-947 induces transcription of TNF-α, IL-6 and IL-8 in ovarian cancer cells and xenograft-bearing mice prior to any viral gene expression and host NF-κB activation. Both RNAi-mediated TNF-α knockdown and anti-TNF-α monoclonal antibody treatment increase virus cytotoxicity in vitro and in IGROV1 intraperitoneal xenografts. The increased efficacy results from suppression of cIAP1 transcription in malignant cells and a consequent increase in caspase-mediated apoptosis. Conclusions. A phase I trial of dl922-947 in women with relapsed ovarian cancer is planned for 2011. Host cell DNA damage is a key determinant of oncolytic adenoviral activity, whilst TNF-α acts as a survival factor in infected cells. Inhibiting both repair of DNA damage and TNF-α could improve anti-tumour activity in future clinical trials. Note: This abstract was not presented at the AACR 101st Annual Meeting 2010 because the presenter was unable to attend. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 591.
Academia Is Not Scutwork Free
Authors: Fredrick B. Hagemeister
Journal: Annals of Internal Medicine (1992)

Letters1 May 1992Academia Is Not Scutwork FreeFredrick B. Hagemeister, MDFredrick B. Hagemeister, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-116-9-779_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the Editors: Dr. Michael Smith, in his letter about scutwork, pointed out that he, too, had to perform mundane tasks on a daily basis in his private practice setting (1, 2). However, his comment that "perhaps the only physicians to escape scutwork are those who stay in academia" seems somewhat short-sighted.Like Dr. Smith, I was bemused by "A Phenomenology of Scut" (2); I, too, wondered what residents expect to find when they emerge into the "real world," and I, too, speak with paramedical personnel, chase down roentgenograms, fill out requisitions, and write all of my own orders and...References1. Smith M. Scutwork and the real world. Ann Intern Med. 1992;116:172. LinkGoogle Scholar2. HaywoodRochwoodSheehanBas RKGE. A phenomenology of scut. Ann Intern med. 1991;115;372-6. LinkGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: Fredrick B. Hagemeister, MDAffiliations: The University of Texas MD Anderson Cancer Center Houston, TX 77030 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 May 1992Volume 116, Issue 9Page: 779-779KeywordsAllied health care professionals ePublished: 1 December 2008 Issue Published: 1 May 1992 PDF downloadLoading ...
Effects of three fat-enriched diets on the arterial pressure of rabbits
Authors: P. G. BURSTYN, W. R. FIRTH
Journal: Cardiovascular Research (1975)

Rabbits were fed diets enriched with proprietary edible fats for 5 weeks, raising the fat content of their diet from 4% to 23%. The diet enriched with animal fat caused a 13.5% rise in arterial pressure. The diet enriched with vegetable oil caused an 8.5% rise in arterial pressure. The diet enriched with butter caused an initial rise of 10% decreasing to 6% by the fifth week. Histological examination of the carotid and renal arteries, and aorta revealed no changes in connective tissue or lipid content as compared with those of control animals. It is concluded that changes in arterial pressure can occur after ingestion of excess dietary lipid, and that these changes are not confined to any class of lipid, or related to its properties as an atherosclerotic agent.
Intra-Uterine Medication
Authors: C. Godson
Journal: BMJ (1879)

be. no doubt that the drug had a direct influence in checking the attacks.In the present instance, this could hardly be due to the elimination of any material from the blood, since there was no urxmic element in the causation of the convulsions.Nor did the effect upon the pulse, as shown by the sphygmograph, appear to be sufficient to make the explanation probable that its mode of action was by causing relaxation of any arterial spasm.As an oxytocic, the pilocarpine ap- peared in this case to be absolutely without any effect.No further convulsions occurred after delivery, and the patient recovered well.
The Clinical Use of Gamma Globulin
Authors: Saul Krugman
Journal: New England Journal of Medicine (1963)

THE purpose of this presentation is to review the information on the uses of normal serum gamma globulin in the management of measles, viral hepatitis, rubella and varicella in the light of recently acquired data and knowledge and to draw some conclusions concerning the future uses of gamma globulin in the management of these diseases.MeaslesIn 1954 Enders and Peebles1 made a historic contribution when they adapted the Edmonston strain of the measles virus to tissue culture. Four years later, on the basis of this development, Enders and his associates2 produced a vaccine consisting of live, attenuated measles virus. . . .
Colorectal Cancer Screening Knowledge, Attitudes, and Beliefs Among Veterans: Does Literacy Make a Difference?
Authors: Nancy C. Dolan, M. Rosario Ferreira, Terry C. Davis, Marian L. Fitzgibbon, Alfred Rademaker, Dachao Liu, Brian P. Schmitt, Nicolle Gorby, Michael Wolf, Charles L. Bennett
Journal: Journal of Clinical Oncology (2004)

To evaluate whether lower literacy is associated with poorer knowledge and more negative attitudes and beliefs toward colorectal cancer screening among veterans without recent colorectal cancer screening.Three hundred seventy-seven male veterans, age 50 years and older, who had not undergone recent colorectal cancer screening, were surveyed about their knowledge, attitudes, and beliefs regarding colorectal cancer screening. Patients' literacy was assessed with the Rapid Estimate of Adult Literacy in Medicine, an individually administered screening test for reading.Thirty-six percent of the 377 men had an eighth grade literacy level or higher. Men with lower literacy were 3.5 times as likely not to have heard about colorectal cancer (8.8% v 2.5%; P =.006), 1.5 times as likely not to know about screening tests (58.4% v 40.9%; P =.0001), and were more likely to have negative attitudes about fecal occult blood testing (FOBT), but not about flexible sigmoidoscopy. Specifically, men with lower literacy skills were two times as likely to be worried that FOBT was messy (26.7% v 13.3%; P =.008), 1.5 times as likely to feel that FOBT was inconvenient (28.7% v 18%; P =.05), and four times as likely to state they would not use an FOBT kit even if their physician recommended it (17.9% v 4.0%; P =.02).Limited literacy may be an overlooked barrier in colorectal cancer screening among veterans.
Ceftazidime treatment in cystic fibrosis: resistant organisms in sputum and faeces.
Authors: A M Dalzell, D Sunderland, C A Hart, D P Heaf
Journal: Thorax (1991)

Ceftazidime was used as the only intravenous agent for treating lower respiratory tract infections in patients with cystic fibrosis. The risks of inducing beta lactamases and conferring antibiotic resistance are high when monotherapy is used; so the emergence of resistant bacteria was studied prospectively in the sputum of 120 patients. The mean age of patients was 9.0 (range 0.3-25) years and there were equal number of male and female patients. Pseudomonas aeruginosa was the only ceftazidime resistant bacterium to be isolated from the respiratory tract, and was identified only in chronically colonised patients. Ceftazidime resistance occurred in 103 (14%) of 750 P aeruginosa isolates, and in 16 of 36 chronically colonised patients. Ceftazidime resistant organisms were isolated from the faeces of 17 of 64 patients investigated. Eighty two per cent of the resistant faecal organisms were single isolates: the same resistant organism in faeces was isolated from successive samples in only two patients. In no case was the ceftazidime resistant enteric isolate the same as that from sputum. Patients chronically colonised by P aeruginosa did not harbour ceftazidime resistant enteric organisms any more than non-colonised patients. The use of ceftazidime as a single intravenous agent in treating chest exacerbations in cystic fibrosis does not induce a reservoir of ceftazidime resistant bacteria.